Literature DB >> 29286076

Activation of transient receptor potential vanilloid 1 protects the heart against apoptosis in ischemia/reperfusion injury through upregulating the PI3K/Akt signaling pathway.

Xiao-Xue Jiang1, Guan-Yu Liu2, Han Lei1, Zuo-Ling Li1, Qing-Ping Feng3, Wei Huang1.   

Abstract

Transient receptor potential vanilloid 1 (TRPV1) is a nonselective cation channel and a molecular integrator of noxious stimuli. TRPV1 activation confers cardiac protection against ischemia/reperfusion (I/R) injury. The present study aimed to investigate whether the cardioprotective effects of TRPV1 were associated with the inhibition of apoptosis via the phosphatidylinositol 3‑kinase (PI3K)/protein kinase B (Akt) and extracellular signal‑regulated protein kinase 1/2 (ERK1/2) signaling pathways. Briefly, the hearts of TRPV1 knockout (TRPV1‑/‑) or wild‑type (WT) mice were isolated and subjected to 30 min of ischemia followed by 60 min of reperfusion in a Langendorff apparatus in the presence or absence of the PI3K inhibitor, LY294002. At the end of reperfusion, infarct size was measured using 2,3,5‑triphenyltetrazolium chloride staining and myocardial apoptosis was assessed by terminal deoxynucleotidyl transferase‑mediated dUTP nick‑end labeling (TUNEL) staining. The expression levels of B‑cell lymphoma 2 (Bcl‑2), Bcl‑2‑associated X protein (Bax), and phosphorylated Akt and ERK1/2 were determined by western blot analysis. There was a significant increase in the extent of infarction and the percentage of TUNEL‑positive cells, and a decrease in the Bcl‑2/Bax ratio, and Akt and ERK1/2 phosphorylation in TRPV1‑/‑ hearts. In addition, treatment with LY294002 increased infarct size and the percentage of TUNEL‑positive cells, and reduced Bcl‑2/Bax expression and Akt phosphorylation in WT hearts, but not in TRPV1‑/‑ hearts, following I/R. Taken together, these data suggested that TRPV1 serves a protective role against myocardial apoptosis during I/R via the PI3K/Akt signaling pathway. In conclusion, activating TRPV1 may be considered a potential approach to protect the heart against I/R injury.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29286076     DOI: 10.3892/ijmm.2017.3338

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  6 in total

1.  Prognostic Significance of Transient Receptor Potential Vanilloid Type 1 (TRPV1) and Phosphatase and Tension Homolog (PTEN) in Epithelial Ovarian Cancer.

Authors:  Gwan Hee Han; Doo Byung Chay; Sanghee Nam; Hanbyoul Cho; Joon-Yong Chung; Jae-Hoon Kim
Journal:  Cancer Genomics Proteomics       Date:  2020 May-Jun       Impact factor: 4.069

Review 2.  Physiological and Pathological Role of TRPV1, TRPV2 and TRPV4 Channels in Heart.

Authors:  Alexandr S Gorbunov; Leonid N Maslov; Amteshwar S Jaggi; Nirmal Singh; Luciano De Petrocellis; Alla A Boshchenko; Ali Roohbakhsh; Vladimir V Bezuglov; Peter R Oeltgen
Journal:  Curr Cardiol Rev       Date:  2019

Review 3.  Capsaicin-Sensitive Sensory Nerves and the TRPV1 Ion Channel in Cardiac Physiology and Pathologies.

Authors:  Tamara Szabados; Kamilla Gömöri; Laura Pálvölgyi; Anikó Görbe; István Baczkó; Zsuzsanna Helyes; Gábor Jancsó; Péter Ferdinandy; Péter Bencsik
Journal:  Int J Mol Sci       Date:  2020-06-23       Impact factor: 5.923

Review 4.  Cannabidiol as a Novel Therapeutic for Immune Modulation.

Authors:  Nadia Peyravian; Sapna Deo; Sylvia Daunert; Joaquin J Jimenez
Journal:  Immunotargets Ther       Date:  2020-08-18

5.  TRPV1 activation and internalization is part of the LPS-induced inflammation in human iPSC-derived cardiomyocytes.

Authors:  Katherine Sattler; Ibrahim El-Battrawy; Lukas Cyganek; Siegfried Lang; Huan Lan; Xin Li; Zhihan Zhao; Jochen Utikal; Thomas Wieland; Martin Borggrefe; Xiaobo Zhou; Ibrahim Akin
Journal:  Sci Rep       Date:  2021-07-19       Impact factor: 4.379

6.  Cardioprotective effect of isorhamnetin against myocardial ischemia reperfusion (I/R) injury in isolated rat heart through attenuation of apoptosis.

Authors:  Yan Xu; Chun Tang; Shengyu Tan; Juan Duan; Hongmei Tian; Yu Yang
Journal:  J Cell Mol Med       Date:  2020-04-19       Impact factor: 5.310

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.